SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease

PLoS One. 2018 Jul 2;13(7):e0200076. doi: 10.1371/journal.pone.0200076. eCollection 2018.

Abstract

Objective: SYNTAX score II (SSII) is a long-term mortality prediction model to guide the decision making of the heart-team between coronary artery bypass grafting or percutaneous coronary intervention (PCI) in patients with left main or three-vessel coronary artery disease. This study aims to investigate the long-term predictive value of SSII for all-cause mortality in patients with one- or two-vessel disease undergoing PCI.

Methods: A total of 628 patients (76% men, mean age: 61±10 years) undergoing PCI due to stable angina pectoris (43%) or acute coronary syndrome (57%), included between January 2008 and June 2013, were eligible for the current study. SSII was calculated using the original SYNTAX score website (www.syntaxscore.com). Cox regression analysis was used to assess the association between continuous SSII and long-term all-cause mortality. The area under the receiver-operating characteristic curve was used to assess the performance of SSII.

Results: SSII ranged from 6.6 to 58.2 (median: 20.4, interquartile range: 16.1-26.8). In multivariable analysis, SSII proved to be an independent significant predictor for 4.5-year mortality (hazard ratio per point increase: 1.10; 95% confidence interval: 1.07-1.13; p<0.001). In terms of discrimination, SSII had a concordance index of 0.77.

Conclusion: In addition to its established value in patients with left main and three-vessel disease, SSII may also predict long-term mortality in PCI-treated patients with one- or two-vessel disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronary Artery Bypass
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / mortality*
  • Coronary Artery Disease / therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention
  • Predictive Value of Tests
  • Prognosis

Grants and funding

ATHEROREMO-IVUS was funded by the Seventh Framework Programme (FP7), theme FP7-HEALTH-2007-2.4.2-1. IBIS-3 was supported by Astra Zeneca, InfraredX and Volcano Corporation. The study was initiated by the investigators, and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. van Geuns received grants from Abbott Vascular and Boston Scientific. Dr. Serruys received personal fees from Abbott Laboratories, AstraZeneca, Biotrinik, Cardialysis, GLG Research, Medtronic, Sino Medical Sciences Technology, Société Europa Digital Publishing, Stentys France, Svelte Medical Systems Philips/Volcano, St. Jude Medical, Qualimed, Xeltis. The specific roles of these authors are articulated in the ‘author contributions’ section.